Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01394029

Enrollment

120

Registered

2011-07-14

Start date

2011-07-31

Completion date

2015-10-31

Last updated

2016-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transfusional Hemosiderosis

Keywords

iron overload, iron chelation, deferasirox, observational

Brief summary

This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

Interventions

DRUGdeferasirox

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to No maximum

Healthy volunteers

Inclusion criteria

-Patients treated with deferasirox for transfusional hemosiderosis according to the local prescribing information. (the patients are either beginning treatment with deferasirox at the time of enrollment in the sentinel site monitoring or are currently under treatment with deferasirox and have started the treatment under prescription up to twelve months prior to enrollment in the sentinal site monitoring.

Exclusion criteria

* Patients with non-transfusional hemosiderosis * Patients treated with deferasirox in an interventional clinical trial Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Serum Creatinine and liver enzyme levels	3 years	Observed over 3 years for each patient
Adverse Drug Reactions	3 years	Observed over 3 years for each patient

Countries

Egypt, Jordan, Spain, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026